3 results
Approved WMORecruiting
Primary objective: to asses the quality of a reservoir which removes leukocytes and lipids combined with the Continuous Autotransfusion System (CATS) regarding the autotransfusion product in general and red blood cell function in particular.…
Approved WMORecruiting
To prove that the RECAP test has the potential of selecting patients who are sensitive to treatment with the PARP inhibitor talazoparib as measured by the PFS rate at 4 months.
Approved WMORecruiting
Primary objectiveTo demonstrate that talazoparib in combination with enzalutamide is superior to placebo in combination with enzalutamide in prolonging investigator--assessed Radiographic Progression-free Survival (rPFS), in participants with mCSPC…